| HOME >> MEDICINE >> TECHNOLOGY |
AETERNA ZENTARIS TAPS VENTANA FOR COMPANION DIAGNOSTIC 165
MDXHEALTH CLOSES AGREEMENT WITH PFIZER TO IDENTIFY A PREDICTIVE
BIOMARKER FOR PARP INHIBITOR THERAPIES 166
FDA GRANTS ROCHE'S PERTUZUMAB PRIORITY REVIEW 166
ALLIANCES 167
BREAST CANCER DRUG AND DIAGNOSTIC PATENT LANDSCAPE 167
BREAST CANCER DRUGS AND PATENT EXPIRY 167
BREAST CANCER PREDICTIVE DIAGNOSTIC PATENTS 167
RECENT PATENT-RELATED ACTIVITY 168
"WHO OWNS PATIENTS' GENES?" AND PATENT ISSUES 168
MYRIAD GENE PATENT RULING 168
NEW BREAST CANCER PATENT AWARDED TO PHIGENIX 169
GALENA BIOPHARMA STRENGTHENS NEUVAX INTELLECTUAL PROPERTY
POSITION 169
CONCLUSIONS 170
CHAPTER 11 REFERENCES 172
LIST OF TABLES
SUMMARY TABLE GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, THROUGH 2016 ($ MILLIONS) 6
TABLE 1 POSSIBLE SIGNS OF BREAST CANCER 10
TABLE 2 DIAGNOSTIC MAMMOGRAM FOR BREAST CANCER 11
TABLE 3 BREAST CANCER GRADES 15
TABLE 4 BIOPSY OR SURGERY SAMPLE TESTING 16
TABLE 5 TESTS USED TO EVALUATE DIFFERENT GENE SETS 17
TABLE 6 IMAGING TESTS THAT DETERMINE IF BREAST CANCER HAS SPREAD 18
TABLE 7 HER2 TESTING AND VARIATIONS 19
TABLE 8 GUIDELINES FOR EARLY DETECTION OF BREAST CANCER IN AVERAGE RISK,
ASYMPTOMATIC WOMEN 25
TABLE 9 BREAST CANCER SCREENING RECOMMENDATIONS BY THE USPSTF 26
TABLE 10 BREAST CANCER PROGNOSTIC FACTORS 30
TABLE 11 BREAST CANCER PREDICTIVE FACTORS 30
TABLE 12 RECURRENCE RATES AT FIVE YEARS IN PATIENTS WITH LYMPH NODES THAT ARE
POSITIVE FOR CANCER (%) 31
TABLE 13 FIVE-YEAR SURVIVAL RATES CORRELATED WITH TUMOR STAGE (%) 31
TABLE 14 PREDICTIVE DIAGNOSTIC FEATURES 32
TABLE 15 CURRENT BIOMARKER TECHNOLOGIES 34
TABLE 16 BIOMARKER USES 35
'/>"/>| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |